The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | The value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the value of bispecific antibodies as a treatment option for patients with multiple myeloma, highlighting the importance of determining the optimal sequencing of these agents alongside CAR-T cells. Dr Nadeem further discusses factors to consider when selecting between these agents, such as toxicities and patient disease profile. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory boards: Janssen, BMS, Takeda, Sanofi, GPCR Therapeutics, GSK
